SITE008-0133

SITE008 (KOR) › SITE008-0133

SITE008-0133

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-02-06

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 197); relationship: RELATED

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-15 (study day 156); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-10 (study day 151); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.